US 12329729 B1Patent grantUnited States

Multi-Cancer Research Compound

Official patent title

Method of treating cancer in a subject

Arabic title: طريقة لعلاج السرطان لدى فرد

Invention

Problem

Current anticancer treatments can injure healthy cells, cause serious adverse effects, and impose substantial costs. New compounds are sought that can inhibit malignant-cell survival through apoptosis-related and inflammation-related pathways.

Why it matters

A chemically tunable anticancer lead could support research across several difficult cancer types and provide a basis for studying relationships between structure, apoptosis signaling, inflammatory markers, and cell response.

Approach

The disclosure proposes substituted compounds of Formula (I), including a preferred Formula (II), or pharmaceutically acceptable salts. It claims administration across several routes and modulation of apoptosis-related and inflammatory genes in selected cancer indications.

Who may benefit

Potential beneficiaries include oncology drug-discovery teams, medicinal chemists, pharmaceutical formulation groups, academic cancer laboratories, and organizations developing apoptosis-targeted therapeutics.

Potential value

The patent defines a broad substituted chemical scaffold, a preferred compound, multiple cancer indications, proposed gene-response mechanisms, dosage range, formulation components, and several administration routes within one therapeutic concept.

Background

Cancer involves uncontrolled growth and spread of abnormal cells and is treated with combinations of surgery, radiation, and systemic drugs. Many chemotherapeutic agents also affect healthy tissue and can cause dose-limiting toxicity. Apoptosis is regulated by caspases, p53, BAX, BCL-2, and related pathways, while inflammatory mediators can influence tumor biology. These mechanisms provide drug-development targets, but a molecular response in laboratory models does not by itself establish patient benefit. The disclosure presents a new substituted compound family for further oncology evaluation.

Technology overview

Formula (I) permits multiple hydrogen, halogen, nitro, cyano, hydroxyl, alkoxy, alkyl, cycloalkyl, arylalkyl, or aryl substitutions, with Formula (II) identified as a preferred embodiment. Claims cover selected lung, prostate, pharyngeal, breast, and cervical cancers, a nominal 0.1–1000 mg/kg range, and oral, parenteral, rectal, topical, transdermal, intralesional, or inhaled delivery. Proposed responses include upregulation of p53, BAX, and caspases and downregulation of BCL-2, MMPs, COX-2, and interleukins.

Potential applications

Preclinical anticancer lead-compound evaluation.
Apoptosis-pathway and inflammatory-marker research.
Medicinal-chemistry optimization of substituted Formula (I) analogues.
Pharmaceutical formulation and delivery-route feasibility studies.
Cell-based studies in selected lung, prostate, breast, cervical, and pharyngeal cancers.

Evidence-supported advantages

Provides a chemically variable scaffold for analogue development.
Identifies a preferred Formula (II) embodiment.
Addresses both apoptosis-related and inflammation-related molecular markers.
Contemplates multiple formulations and routes of administration.
Covers several specified cancer indications for further investigation.

Development stage

A compound family, synthesis concept, pharmaceutical compositions, and claimed molecular responses are described; the supplied evidence does not establish animal efficacy, safety, or clinical benefit. The development stage was not independently verified.

Commercial opportunity

The scaffold may support early-stage licensing or sponsored oncology research. Advancement requires confirmed structure and potency, normal-cell selectivity, reproducible mechanism studies, pharmacokinetics, formulation, animal efficacy and toxicology, manufacturing controls, regulatory submissions, and phased clinical trials before any therapeutic use in humans.

Patent classifications

WIPO IPC

A61K31/15Preparations for medical, dental or toiletry purposes
A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations

CPC

A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
C07C391/02Acyclic or carbocyclic compounds
A61K31/15Preparations for medical, dental or toiletry purposes

Inventors

First inventorTarek Ahmed Yousef
InventorSaad Shaaban
InventorAhmed A. Al-Karmalawy
InventorAyman Abo Elmaaty

Keywords

anticancer compound
Formula I
Formula II
apoptosis
caspases
BCL-2
inflammatory markers
oncology drug discovery

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.